Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.41 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 9/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157260 | 0.86 | CHEK1 (0.54) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL179562 | 0.86 | CHEK1 (0.54) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL12777831 | 0.85 | MAP3K7 (0.56) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL15631612 | 0.82 | CHEK1 (0.50) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL3224390 | 0.82 | CHEK1 (0.50) | CHEK1MAP3K7TAB1JAK2JAK3 | |
| SCHEMBL2024785 | 0.82 | BTK (0.58) | CHEK1BTK | |
| SCHEMBL3221026 | 0.81 | CHEK1 (0.49) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL16764899 | 0.81 | CHEK1 (0.49) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL28068449 | 0.79 | MAP3K7 (0.47) | CHEK1MAP3K7TAB1JAK2JAK3 | |
| SCHEMBL19898256 | 0.77 | BTK (0.64) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118359638-A | Compound serving as RET kinase inhibitor and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117164592-A | Pyrrolo-aminopyrimidine compounds, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-12-05 | — | — | CN | disclosed |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2021105335-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011018894-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | RAQUALIA PHARMA INC. (JP) | 2011-02-17 | — | — | WO | disclosed |
| WO-2008075007-A1 | MORPHOLINO-SUBSTITUTED BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS ANTI CANCER AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075007-A1 | MORPHOLINO-SUBSTITUTED BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS ANTI CANCER AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-0831829-B1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | CHEK1 718/4885NOTUM 2929/4885MAP3K7 1062/4885 |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | JAK2, JAK3, JAK1 | CHEK1 699/4885NOTUM 2941/4885MAP3K7 102/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | CHEK1 339/4885NOTUM 3663/4885MAP3K7 31/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | CHEK1 320/4885NOTUM 3744/4885MAP3K7 29/4885 |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | CHEK1 3567/4885NOTUM 2947/4885MAP3K7 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.